Propanc Biopharma Advances GMP Manufacture and Regulatory Workstreams

With a Phase 1b first-in-human study of PRP targeting a Q1 2027 start, Propanc Biopharma is running manufacturing, bio-analytics, and regulatory workstreams in parallel, a compressed timeline that illustrates both the discipline and the execution risk inherent in small-biotech clinical supply preparation.

On the manufacturing side, GMP manufacture of finished drug product is underway. A small-scale technology transfer run has been completed, two scale-up runs are scheduled for this month, and an engineering run is planned for late October 2026. Raw drug substance supply has been secured following vendor audit and qualification, a prerequisite step that, if delayed, typically cascades directly into study start timelines.

Bio-analytics work is tracking alongside manufacturing. PK method validation has commenced, anti-drug antibody assay development is in progress, and in-use stability testing of the finished PRP formulation is scheduled. For QA leads, the sequencing here is tight: stability data must be available before the clinical protocol can lock dosing and storage parameters with confidence.

The regulatory and ethics pathway is equally compressed. Supporting documentation for Human Research Ethics Committee (HREC) submission, including the Investigator's Brochure, a briefing document, and the clinical trial protocol, is in preparation. Investigators at Australian trial sites are to receive documents for feasibility assessment ahead of a planned HREC submission in November 2026. That leaves a narrow window between ethics approval and the Q1 2027 enrolment target for a multicenter, open-label study enrolling up to 50 patients with advanced solid tumors across pancreatic, ovarian, and refractory prostate cancer indications.

Preclinical data underpinning the program includes greater than 90% mean tumor growth inhibition in orthotopic and patient-derived xenograft models of pancreatic ductal adenocarcinoma, a median overall survival extension of more than 2.5-fold versus controls, and evidence of enhanced sensitivity to gemcitabine/nab-paclitaxel in chemo-resistant cells. Limited compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival with no severe treatment-related adverse events, context that will inform the dose-escalation design of Part A of the study.

Clinical delivery will be supported through a Memorandum of Understanding with Avance Clinical Pty Ltd, a full-service CRO headquartered in Australia with more than 30 years of early-phase experience across Asia Pacific, North America, and Europe.

The engineering run planned for late October 2026 represents the next concrete checkpoint against which manufacturing readiness for the Q1 2027 study start can be measured.

Source: Propanc Biopharma via GlobeNewswire, 29 September 2026.